The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL.
Heiss MM, et al. Among authors: schmittel a.
Int J Cancer. 2010 Nov 1;127(9):2209-21. doi: 10.1002/ijc.25423.
Int J Cancer. 2010.
PMID: 20473913
Free PMC article.
Clinical Trial.